There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

For people taking Ozempic, Wegovy or other GLP-1 medications, Thanksgiving may look a little different. Experts give tips on ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual ...

The global chocolate giant’s Chief Executive Officer and Chairman, Michele Buck, commented on the relationship between GLP-1 ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...

Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as ...